Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling.
Date
2019-10-28Journal
Journal of General Internal MedicinePublisher
Springer NatureType
Article
Metadata
Show full item recordSee at
https://doi.org/10.1007/s11606-019-05460-2https://link.springer.com/article/10.1007%2Fs11606-019-05460-2
Sponsors
This study was funded with nonspecific faculty research funds provided by the University of Maryland, Baltimore, to Dr. Doshi.Identifier to cite or link to this item
http://hdl.handle.net/10713/11247ae974a485f413a2113503eed53cd6c53
10.1007/s11606-019-05460-2
Scopus Count
Collections
Related articles
- FDA Regulation of Prescription Drugs.
- Authors: Gassman AL, Nguyen CP, Joffe HV
- Issue date: 2017 Feb 16
- Pharmaceuticals and Medical Devices: FDA Oversight.
- Authors: White RS, Thomson Reuters Accelus.
- Issue date: 2017 Dec 26
- New Drugs Approved in 2019.
- Authors: Ebied AM, Patel KH, Cooper-DeHoff RM
- Issue date: 2020 Jun
- Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
- Authors: Frank C, Himmelstein DU, Woolhandler S, Bor DH, Wolfe SM, Heymann O, Zallman L, Lasser KE
- Issue date: 2014 Aug
- Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
- Authors: Ostroff C, Lee CE, McMeekin J
- Issue date: 2011 Aug